+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allergic Rhinitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 180 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645027
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Drugs In Development, 2022, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 13, 17, 14, 4, 12 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 4 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Allergic Rhinitis - Overview
  • Allergic Rhinitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Allergic Rhinitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
  • Allergic Rhinitis - Drug Profiles
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
  • Featured News & Press Releases
  • Jul 22, 2022: Revelation Biosciences announces topline data for phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
  • Jul 14, 2022: Revelation Biosciences inc. completes database lock for its phase 1b clear clinical study of REVTx-99b for the treatment of allergic rhinitis
  • Jun 13, 2022: Revelation Biosciences announces completion of dosing for a phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
  • May 23, 2022: Revelation Biosciences announces Safety Monitoring Committee recommendation for continuing evaluation of REVTx-99b for the treatment of allergic rhinitis
  • Apr 07, 2022: Grand Pharmaceutical Group : Phase III clinical trial of global innovative drug Ryaltris compound nasal spray successfully completed the first patient enrollment in China
  • Mar 16, 2022: Wowu Bio: first subject enrolled in the clinical trial after the launch of Artemisia annua pollen allergen sublingual drops
  • Mar 01, 2022: Miravo Healthcare announces the Canadian commercial launch of Blexten for patients 4 years of age and older
  • Jan 24, 2022: Zhejiang Wolwo Bio-Pharma announcement on obtaining the summary report of the phase III clinical trial of Artemisia annua Pollen Allergen Sublingual drops for children with rhinitis
  • Jan 18, 2022: Revelation Biosciences announces first patient enrolled and dosed in phase 1b clinical study of REVTx-99 for the treatment of allergic rhinitis
  • Jan 14, 2022: Glenmark Specialty S.A. (Switzerland) receives NDA approval by the United States Food and Drug Administration (FDA) for Ryaltris nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older
  • Nov 15, 2021: Revelation Biosciences announces initiation of a phase 1b clinical study of REVTx-99 for the experimental treatment of allergic rhinitis and chronic nasal congestion
  • Oct 20, 2021: The global innovative drug Ryaltris compound nasal spray has been granted phase three clinical trial approval
  • Sep 30, 2021: Glenmark receives marketing approval for Ryaltris, an innovative combination nasal spray, in 13 countries across the EU and UK
  • Jun 23, 2021: Nasus Pharma announces positive results from a pilot clinical study of FMXIN002 intranasal powder epinephrine spray in patients with Seasonal Allergic Rhinitis
  • Jun 08, 2021: Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Allergic Rhinitis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by ALK-Abello AS, 2022
  • Allergic Rhinitis - Pipeline by Alkem Laboratories Ltd, 2022
  • Allergic Rhinitis - Pipeline by Allovate LLC, 2022
  • Allergic Rhinitis - Pipeline by AOBiome LLC, 2022
  • Allergic Rhinitis - Pipeline by ASIT Biotech SA, 2022
  • Allergic Rhinitis - Pipeline by AtoGen Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, 2022
  • Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
  • Allergic Rhinitis - Pipeline by Dobecure SL, 2022
  • Allergic Rhinitis - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, 2022
  • Allergic Rhinitis - Pipeline by EmphyCorp Inc, 2022
  • Allergic Rhinitis - Pipeline by Eurofarma Laboratorios SA, 2022
  • Allergic Rhinitis - Pipeline by Faes Farma SA, 2022
  • Allergic Rhinitis - Pipeline by FunPep Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Genu Pharma Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by GL Pharm Tech Corp, 2022
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, 2022
  • Allergic Rhinitis - Pipeline by Inimmune Corp, 2022
  • Allergic Rhinitis - Pipeline by Inmunotek SL, 2022
  • Allergic Rhinitis - Pipeline by Liminal BioSciences Inc, 2022
  • Allergic Rhinitis - Pipeline by Link Health Group, 2022
  • Allergic Rhinitis - Pipeline by Marinomed Biotech AG, 2022
  • Allergic Rhinitis - Pipeline by MD Healthcare Inc, 2022
  • Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
  • Allergic Rhinitis - Pipeline by Nasus Pharma Ltd, 2022
  • Allergic Rhinitis - Pipeline by Navipharm Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by NeuCen BioMed Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Palo Alto pharmaceuticals Inc, 2022
  • Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
  • Allergic Rhinitis - Pipeline by PharmaKing Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Raphas Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
  • Allergic Rhinitis - Pipeline by Revelation Biosciences Inc, 2022
  • Allergic Rhinitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
  • Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, 2022
  • Allergic Rhinitis - Pipeline by Sama Pharm Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, 2022
  • Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, 2022
  • Allergic Rhinitis - Pipeline by Stallergenes Greer Ltd, 2022
  • Allergic Rhinitis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
  • Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, 2022
  • Allergic Rhinitis - Pipeline by United Biomedical Inc, 2022
  • Allergic Rhinitis - Pipeline by Vactech Oy, 2022
  • Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Yuyu Pharma Inc, 2022
  • Allergic Rhinitis - Pipeline by Zhejiang Wolwo Bio-Pharmaceutical Co Ltd, 2022
  • Allergic Rhinitis - Pipeline by Zydus Lifesciences Ltd, 2022
  • Allergic Rhinitis - Dormant Projects, 2022
  • Allergic Rhinitis - Discontinued Products, 2022
  • Allergic Rhinitis - Discontinued Products, 2022 (Contd..1)

List of Figures
  • Number of Products under Development for Allergic Rhinitis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Alkem Laboratories Ltd
  • Allovate LLC
  • AOBiome LLC
  • ASIT Biotech SA
  • AtoGen Co Ltd
  • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Chrysalis BioTherapeutics Inc
  • CSPC Pharmaceutical Group Ltd
  • Dobecure SL
  • DongKoo Bio & Pharma Co Ltd
  • Emergo Therapeutics Inc
  • EmphyCorp Inc
  • Eurofarma Laboratorios SA
  • Faes Farma SA
  • FunPep Co Ltd
  • Genu Pharma Co Ltd
  • GL Pharm Tech Corp
  • Glenmark Pharmaceuticals Ltd
  • HAL Allergy BV
  • Inimmune Corp
  • Inmunotek SL
  • Liminal BioSciences Inc
  • Link Health Group
  • Marinomed Biotech AG
  • MD Healthcare Inc
  • Mitsubishi Tanabe Pharma Corp
  • Nasus Pharma Ltd
  • Navipharm Co Ltd
  • NeuCen BioMed Co Ltd
  • Oneness Biotech Co Ltd
  • Palo Alto pharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • PharmaKing Co Ltd
  • Raphas Co Ltd
  • Regeneron Pharmaceuticals Inc
  • Revelation Biosciences Inc
  • Revolo Biotherapeutics Ltd
  • Roxall Medizin GmbH
  • Sama Pharm Co Ltd
  • Sedor Pharmaceuticals LLC
  • Shouyao Holding Co Ltd
  • Siolta Therapeutics Inc
  • Stallergenes Greer Ltd
  • Synokem Pharmaceuticals Ltd
  • The Geneva Biotech Center SA
  • United Biomedical Inc
  • Vactech Oy
  • Wuhan Yicheng Biotechnology Co Ltd
  • Yuyu Pharma Inc
  • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • Zydus Lifesciences Ltd